COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00082316
Recruitment Status : Completed
First Posted : May 7, 2004
Last Update Posted : January 11, 2008
Information provided by:

Brief Summary:
This study is a randomized, open-label multi-center evaluation of the tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of one of three 4% lidocaine-based local anesthetic products. Eligible subjects will have moderate to severe neuropathic pain secondary to painful diabetic neuropathy (PDN), postherpetic neuralgia (PHN) or HIV-associated neuropathy (HIV-AN), with average numeric pain rating scale (NPRS) scores during screening of 3 to 8 (inclusive).

Condition or disease Intervention/treatment Phase
Herpes Zoster Neuralgia Pain HIV Infections Peripheral Nervous System Diseases Diabetic Neuropathies Diabetes Mellitus Polyneuropathies Drug: Capsaicin Dermal Patch Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Shingles
Drug Information available for: Capsaicin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Eligibility Criteria:

  • Must have had for at least 3 months painful diabetic neuropathy, or postherpetic neuralgia, or painful HIV-associated neuropathy, with moderate to severe pain on average.
  • Must not have significant pain due to other causes (for example, arthritis).
  • Must have intact skin at the treatment area.
  • Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (12 weeks).
  • Must not use topical pain medications on painful areas.
  • Must be able to comply with study requirements such as completing daily pain diary and attending study visits and refrain from extensive travel during study participation.
  • Must be at least 18 years old, not pregnant, and able to take care of self independently, with only occasional assistance if needed.
  • No significant medical problems of the heart, kidneys, liver or lungs, or cancer.
  • No history or current problem with substance abuse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00082316

Layout table for location information
United States, Alabama
NeurogesX Investigational Site
Huntsville, Alabama, United States, 35801
NeurogesX Investigational Site
Mobile, Alabama, United States, 36608
United States, Arizona
NeurogesX Investigational Site
Phoenix, Arizona, United States, 85023
United States, California
NeurogesX Investigational Site
Fountain Valley, California, United States, 92708
NeurogesX Investigational Site
Los Gatos, California, United States, 95032
United States, Colorado
NeurogesX Investigational Site
Denver, Colorado, United States, 80209
United States, Florida
NeurogesX Investigational Site
Clearwater, Florida, United States, 33765
NeurogesX Investigational Site
New Port Richey, Florida, United States, 34652
NeurogesX Investigational Site
North Miami, Florida, United States, 33161
NeurogesX Investigational Site
Plantation, Florida, United States, 33324
United States, Iowa
NeurogesX Investigational Site
West Des Moines, Iowa, United States, 50265
United States, Massachusetts
NeurogesX Investigational Site
Wellesley Hills, Massachusetts, United States, 02481-2106
United States, Missouri
NeurogesX Investigational Site
Saint Louis, Missouri, United States, 63108
United States, New Jersey
NeurogesX Investigational Site
Greensboro, New Jersey, United States, 27408
United States, Pennsylvania
NeurogesX Investigational Site
Duncansville, Pennsylvania, United States, 16635
United States, Texas
NeurogesX Investigational Site
San Antonio, Texas, United States, 78229
United States, Utah
NeurogesX Investigational Site
Salt Lake City, Utah, United States, 84106
Sponsors and Collaborators
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00082316    
Other Study ID Numbers: C111
First Posted: May 7, 2004    Key Record Dates
Last Update Posted: January 11, 2008
Last Verified: January 2008
Keywords provided by NeurogesX:
Dermal assessment
Pain assessment
Herpes zoster
HIV Infections
Peripheral Nervous System Diseases
Diabetic Neuropathies
Diabetes Mellitus
Complementary Therapies
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Herpes Zoster
Diabetic Neuropathies
Nervous System Diseases
Peripheral Nervous System Diseases
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Neuromuscular Diseases
Neurologic Manifestations
Diabetes Complications
Varicella Zoster Virus Infection
Herpesviridae Infections
DNA Virus Infections
Dermatologic Agents
Sensory System Agents